SYSTEMATIC REVIEW article
Front. Genet.
Sec. Cancer Genetics and Oncogenomics
This article is part of the Research TopicLiquid biopsy biomarkers for cancer detection, treatment monitoring, and clinical outcome predictionView all articles
The impact of circulating tumor DNA on the prognosis of liver cancer and its predictive value: A Meta analysis
Provisionally accepted
- Taizhou Jiaojiang Maternal and Child Health Care Hospital, Taizhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: ctDNA is a promising biomarker in oncology. However, its prognostic and predictive value in HCC remains underexplored. This meta-analysis aims to evaluate the prognostic impact of ctDNA in HCC and its predictive value for recurrence. Methods: A systematic review and meta-analysis were performed following PRISMA guidelines. PubMed, Embase, Web of Science, and CNKI were searched up to June 1, 2025, for studies assessing ctDNA in HCC patients with reported survival outcomes or predictive accuracy. Studies reporting hazard ratios for overall or disease-free survival, or AUCs for prediction, were included. Two reviewers independently screened studies and assessed quality using the Newcastle–Ottawa Scale. Meta-analyses used random-or fixed-effects models depending on heterogeneity, with sensitivity analyses performed to assess robustness. Results: A total of 219 records were screened from PubMed, Embase, Web of Science, and CNKI, and 8 studies comprising 1,907 patients were included. ctDNA positivity was significantly associated with poorer OS, with a pooled HR of 2.34 (95% CI 1.96– 2.78; p < 0.0001). Moderate heterogeneity was observed (I² = 32.2%). Sensitivity analyses confirmed the robustness of this finding. Two studies assessed the predictive value of ctDNA for RFS, yielding a pooled AUC of 0.66 (95% CI 0.47–0.86; I² = 65.7%). Discriminative accuracy was higher when ctDNA was detected postoperatively (AUC range: 0.57–0.77), suggesting its potential role in identifying minimal residual disease. Conclusion: ctDNA is associated with adverse prognosis in HCC and may offer moderate predictive accuracy for recurrence. Standardized protocols for sampling and analysis are required to facilitate broader clinical translation.
Keywords: circulating tumor DNA, Hepatocellular Carcinoma, liquid biopsy, Meta-analysis, prognosis, Recurrence, Survival Prediction
Received: 15 Dec 2025; Accepted: 03 Feb 2026.
Copyright: © 2026 Wu, Ke, Zhu, Dong and Luan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jinqian Luan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.